SCHEDULE: Two Seas Capital Boosts Adaptimmune Stake to 8.5%

Two Seas Capital LP and its affiliates have increased their beneficial ownership in Adaptimmune Therapeutics PLC to 8.5% of ordinary shares as of June 30, 2025.

Summary

• Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi collectively report beneficial ownership of 135,484,206 Ordinary Shares of Adaptimmune Therapeutics PLC.
• This ownership represents 8.5% of the total Ordinary Shares outstanding as of June 30, 2025.
• The reported shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital LP serves as investment manager.
• The beneficial ownership includes sole voting power and sole dispositive power over all 135,484,206 shares.
• The 135,484,206 Ordinary Shares are represented by 22,580,701 American Depositary Shares (ADS).
• The percentage of class is calculated based on 1,590,309,546 Ordinary Shares outstanding on June 30, 2025, as disclosed in Adaptimmune Therapeutics PLC's Form 10-Q filed on August 13, 2025.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Adaptimmune Therapeutics PLC.

Sentiment

Score: 5

Explanation: This filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• Two Seas Capital LP, a Delaware limited partnership, holds a significant 8.5% beneficial ownership stake in Adaptimmune Therapeutics PLC, indicating substantial institutional investment.
• The investment is declared to be for passive purposes, not intended to influence or change control of the issuer, which can provide stability.

Negatives

• No negative aspects related to Adaptimmune Therapeutics PLC's operations or financial health are disclosed in this beneficial ownership report.

Risks

• This filing, a beneficial ownership report, does not detail specific risks related to Adaptimmune Therapeutics PLC's business or operations.

Future Outlook

This beneficial ownership report does not contain any forward-looking statements or guidance from Adaptimmune Therapeutics PLC.

Management Comments

• Two Seas Capital LP certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Adaptimmune Therapeutics PLC.

Industry Context

This filing is a standard disclosure of a passive beneficial ownership stake by an investment firm in a publicly traded biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional holder's passive stake in the company.

Key Dates

Keywords

Adaptimmune Therapeutics, Two Seas Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals, Investment